TOP HEADLINES

Featured Story

  • Autoimmune experts discover a new pathway for multiple sclerosis R&D

    Blocking the cascade of events that trigger autoimmune disease is a key focus in multiple sclerosis research. And a multidisciplinary team of investigators in Singapore says they have figured out one piece of the puzzle that could offer a new discovery pathway for the disease.

UC Irvine investigators spotlight a new class of 'chemosensitizers'

Scientists with the UC Irvine School of Medicine and the Italian Institute of Technology have spotlighted what they call the "very first class" of acid ceramidase inhibitors that could eventually go on to help amp up the effectiveness of chemotherapies.

Rodent studies point to a new target for ovarian cancer R&D

Building on earlier work involving the angiogenesis inhibitor thrombospondin-1, or TSP-1, investigators say they've been able to demonstrate in animal studies that a segment of that protein acts to inhibit the growth of ovarian cancer cells. And the use of that therapeutic approach allowed for more effective use of small doses of chemotherapy in treating the deadly disease.

U.K.'s MRC outlicenses Parkinson's discovery program to China's Yabao

The U.K. medical research institute MRC Technology--the tech transfer arm of the government's big Medical Research Council--has struck a deal to collaborate with China's Yabao Pharmaceutical on new Parkinson's drugs for the Asian market. In the deal, Yabao will dedicate part of its research effort to an unidentified kinase target for neurodegeneration.

Salk method highlights protein-protein interactions in cancer

Scientists at Salk say they have identified a new method to detect "fleeting" protein-protein interactions, a key focus in oncology R&D.

Structural modeling at Scripps points to better Ebola drug cocktails

One of the drug cocktails now in preclinical development for Ebola, ZMapp, has been used for a small group of emergency cases. And now two Scripps investigators have come up with a 3-D model to show where its three antibodies stick to the virus, pointing to new and better therapies as well as informing work on other such cocktail therapies.

MORE NEWS